Scarica l'app Stockscreener
21.68
7.54%
1.52
Dopo l'orario di chiusura:
21.68
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DNLI Giù?
Forum
Previsione
Denali Therapeutics Inc Borsa (DNLI) Ultime notizie
FDA clears Denali Therapeutics drug as first brain-penetrating biologic for rare disease - MSN
Retail Surge: Can Denali Therapeutics Inc withstand a market correction2026 Drop Watch & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Pullback Watch: Is Denali Therapeutics Inc stock suitable for long term investingQuarterly Trade Report & Smart Money Movement Tracker - baoquankhu1.vn
Assessing Denali Therapeutics (DNLI) Valuation After Recent Share Pullback And Pipeline Growth Expectations - Sahm
Pullback Watch: Can Denali Therapeutics Inc withstand a market correctionMarket Activity Summary & Community Verified Swing Trade Signals - baoquankhu1.vn
Retail Surge: What are analysts price targets for Denali Therapeutics IncPrice Action & Risk Controlled Swing Alerts - baoquankhu1.vn
Trading the Move, Not the Narrative: (DNLI) Edition - Stock Traders Daily
How AVLAYAH’s Accelerated Approval and Takeda Exit Will Impact Denali Therapeutics (DNLI) Investors - Sahm
Aug Opening: Is Denali Therapeutics Inc forming higher highs and higher lowsGap Down & Daily Volume Surge Signals - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Denali Therapeutics (DNLI) and Fennec Pharmaceuticals (FENC) - The Globe and Mail
Arista Networks To Rally Around 43%? Here Are 10 Top Analyst Forecasts For Tuesday - Sahm
Denali Stock Falls as Partner Takeda Ends Collaboration Deal - Yahoo Finance
H.C. Wainwright Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $42 - Moomoo
Denali Therapeutics (NASDAQ:DNLI) Given New $34.00 Price Target at Robert W. Baird - MarketBeat
Denali shares drop after Takeda terminates partnership agreement - Bitget
Denali regains rights to DNL593 from Takeda - The Pharma Letter
BTIG Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $39 - Moomoo
Denali Therapeutics (NASDAQ:DNLI) Shares Down 4.9%Here's What Happened - MarketBeat
Takeda Exits Dementia Drug Partnership With Denali TherapeuticsHere's Why - Benzinga
Takeda Breaks Up With Denali, Dumps Dementia Drug - BioSpace
Capricorn Fund Managers Ltd Acquires New Position in Denali Therapeutics Inc. $DNLI - MarketBeat
Denali Regains Full Control Of DNL593 As It Advances Toward Key 2026 Readout - RTTNews
Takeda (TAK) Ends Collaboration on Drug Development with Denali Therapeutics - GuruFocus
SG Americas Securities LLC Increases Stock Position in Denali Therapeutics Inc. $DNLI - MarketBeat
Denali Therapeutics Inc. $DNLI Stake Increased by Aberdeen Group plc - MarketBeat
Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Average Rating of "Moderate Buy" from Analysts - marketbeat.com
DNLI Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
DNLI Technical Analysis & Stock Price Forecast - Intellectia AI
Denali Reclaims DNL593 Rights Concentrating Dementia Drug Risks And Upside - Sahm
Denali Therapeutics Inc. (DNLI) stock price, news, quote and history - Yahoo Finance Singapore
Denali Regains DNL593 Rights After Takeda Collaboration Ends - TipRanks
Denali Therapeutics Regains Full Rights to DNL593 as Takeda Ends 2018 Collaboration - TradingView
Denali Therapeutics Inc. And Takeda Terminate Collaboration Agreement For DNL593 - marketscreener.com
Takeda exits DNL593 deal; Denali (NASDAQ: DNLI) takes full control of FTD-GRN drug - Stock Titan
Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN) - The Manila Times
Takeda exits dementia drug pact, Denali targets trial data by 2026 end - Stock Titan
Aug Opening: Is Denali Therapeutics Inc a turnaround storyQuarterly Market Review & Community Verified Trade Alerts - baoquankhu1.vn
DNLI Stock Price, Quote & Chart | DENALI THERAPEUTICS INC (NASDAQ:DNLI) - ChartMill
Biopharma M&A Heats Up, Rare Diseases Win Three Approvals, Wave Crashes - BioSpace
Market Overview: Will Denali Therapeutics Inc outperform small cap indexesQuarterly Market Review & Weekly High Return Opportunities - baoquankhu1.vn
Pullback Watch: Will Denali Therapeutics Inc benefit from government policy2026 AllTime Highs & Capital Protection Trade Alerts - baoquankhu1.vn
The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step - Benzinga
Denali Therapeutics Receives $200 Million Following FDA Accelerated Approval of Tividenofusp Alfa and Royalty Agreement Closing - minichart.com.sg
Denali Therapeutics scores $200 million shortly after first drug approval - The Business Journals
Denali Therapeutics Secures $200 Million Royalty Funding - TipRanks
Denali Therapeutics receives $200 million from royalty agreement after FDA approval - Investing.com India
Denali Therapeutics (NASDAQ: DNLI) closes $200M royalty deal after FDA OK - Stock Titan
Denali Therapeutics (DNLI) Is Down 13.9% After First BBB-Crossing Hunter Therapy Wins FDA NodWhat's Changed - Yahoo Finance
Is Denali Therapeutics’ (DNLI) First Brain-Penetrant Biologic Redefining Its Platform Value Proposition? - simplywall.st
(DNLI) Volatility Zones as Tactical Triggers - Stock Traders Daily
Denali Therapeutics Inc. (DNLI) Discusses FDA Approval and Commercial Launch Plans for AVLAYAH for Hunter SyndromeSlideshow (NASDAQ:DNLI) 2026-03-27 - Seeking Alpha
Denali Therapeutics (DNLI): Goldman Sachs Raises Price Target to $40 | DNLI Stock News - GuruFocus
Stifel Nicolaus Issues Positive Forecast for Denali Therapeutics (NASDAQ:DNLI) Stock Price - Defense World
Denali Therapeutics (NASDAQ:DNLI) Price Target Raised to $42.00 at HC Wainwright - Defense World
(DNLI.O) | Stock Price & Latest News - Reuters
FDA Approval for Denali Therapeutics Blazes a New Trail for Brain-Penetrating Drugs - MedCity News
Vanguard disaggregation: no beneficial DNLI shares reported (DNLI) - Stock Titan
Denali Receives FDA Approval for Hunter Syndrome Treatment, Shares Rise - Bitget
Denali Wins FDA Nod for Hunter Syndrome Drug, Stock Up - Yahoo Finance
Morgan Stanley Forecasts Strong Price Appreciation for Denali Therapeutics (NASDAQ:DNLI) Stock - MarketBeat
Denali Therapeutics (NASDAQ:DNLI) Stock Price Down 5.7%Time to Sell? - MarketBeat
2.69%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):